BerGenBio has not paid any dividends for the year ended 31 December 2020 or any previous year. The Company is focusing on the development of novel pharmaceutical products and does not anticipate paying any cash dividend until sustainable profitability is achieved.
For mandatory announcements relating to trades by primary insiders press here.
For a list of primary insiders please see here.
The Company’s register of shareholders with the VPS is administrated by DNB:
DNB Bank ASA, Verdipapirservice
Dronning Eufemias gate 30
BerGenBio is audited by EY:
ERNST & YOUNG AS, organisation number 976 389 387
Dronning Eufemias gate 6
Jonas Lies vei 91
Organisation number: 992 219 688
ISIN: NO 001 0650013